A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

Cancer cells are quick to develop resistance to anti-tumor drugs. New research by scientists from the University of ...

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and ...

Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory ...

Covalent inhibitors represent a class of small molecules that form irreversible or quasi‐irreversible bonds with their protein targets, offering enhanced potency, prolonged duration of action and the ...

Pancreatic cancer is one of the deadliest cancers and the third-leading cause of cancer-related death in the United States.

Blocking the NAD hydrolase may save axons from neurodegeneration, if researchers can figure out a safe way to do it ...

Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors– First patient dosed in Phase 1b/2a ALS study with NB-4746, ...

Enabled Design of a Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation in Parkinson's Disease," will detail how the company's Hybrid AI Platform, built together with Expert Systems, Inc., guided ...